Duality Advisers LP Has $3.34 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

Duality Advisers LP raised its position in Bristol-Myers Squibb (NYSE:BMY) by 1,700.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 65,143 shares of the biopharmaceutical company’s stock after purchasing an additional 61,525 shares during the period. Duality Advisers LP’s holdings in Bristol-Myers Squibb were worth $3,342,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the stock. Pacer Advisors Inc. lifted its position in shares of Bristol-Myers Squibb by 48.0% during the 4th quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock valued at $401,806,000 after acquiring an additional 2,540,360 shares during the period. AustralianSuper Pty Ltd acquired a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $86,965,000. Mizuho Markets Americas LLC acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at $82,405,000. Northern Trust Corp lifted its position in shares of Bristol-Myers Squibb by 5.8% during the 3rd quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after acquiring an additional 1,394,158 shares during the period. Finally, Invesco Ltd. raised its holdings in Bristol-Myers Squibb by 8.6% during the third quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock worth $905,806,000 after buying an additional 1,240,902 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY opened at $49.14 on Tuesday. The firm has a market cap of $99.59 billion, a P/E ratio of 12.73, a PEG ratio of 1.48 and a beta of 0.39. The firm has a 50-day moving average of $51.22 and a 200 day moving average of $51.38. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. Bristol-Myers Squibb has a fifty-two week low of $47.58 and a fifty-two week high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.82 earnings per share. On average, research analysts expect that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.88%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BMY shares. Wells Fargo & Company upped their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.